Seer Inc Asset Turnover Ratio (SEER), as of third quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket
 


Seer Inc   (NASDAQ: SEER)
 

Seer Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Seer Inc 's asset turnover ratio has remained unchanged compare to previous quarter at 0.04 in the third quarter (Sep 30 2026)

Within sector 19 more businesses have achieved higher asset turnover ratio. While ranking the asset turnover ratio, among all other companies, it is fair to say, that the company's position has deteriorated in the Third Quarter 2026 compared to the preceding quarter from 2876 to 3403.

Asset Turnover Ratio Definition



SEER Asset Turnover Ratio (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Asset Change -20.67 % 100.06 % -21.63 % -14.18 % -14.67 %
Y / Y Revenue Change -3.14 % -0.29 % -51.19 % 3.14 % 4.37 %
Asset Turnover Ratio (TTM) 0.04 0.04 0.05 0.05 0.05
SEER's Total Ranking # 3403 # 2876 # 2895 # 2163 #
Seq. Asset Change -62.06 % 137.08 % -8.09 % -4.06 % -4.3 %
Seq. Revenue Change 28.34 % 56.51 % -61.76 % 26.11 % 32.11 %



Asset Turnover Ratio Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 20
Healthcare Sector # 506
Overall Market # 3403

Asset Turnover Ratio Statistics
High Average Low
1.93 0.38 -0.09
(Dec 31 2014)   (Sep 30 2014)







Companies with similar Asset Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Assets at quarter ending Sep 30 2026
Wave Life Sciences Ltd   0.15 $ 87.296  Millions$ 572.074  Millions
Omniab Inc   0.14 $ 40.211  Millions$ 293.935  Millions
Standard Biotools Inc   0.14 $ 83.592  Millions$ 617.355  Millions
Ligand Pharmaceuticals Incorporated  0.14 $ 253.827  Millions$ 1,879.020  Millions
Bicycle Therapeutics Plc  0.13 $ 83.528  Millions$ 635.938  Millions
Kura Oncology Inc   0.12 $ 79.314  Millions$ 636.301  Millions
Voyager Therapeutics Inc   0.12 $ 25.108  Millions$ 211.603  Millions
Monte Rosa Therapeutics Inc   0.11 $ 70.325  Millions$ 643.493  Millions
Beam Therapeutics Inc   0.10 $ 146.644  Millions$ 1,404.350  Millions
Opus Genetics Inc   0.10 $ 7.914  Millions$ 76.323  Millions
Coya Therapeutics Inc   0.10 $ 4.689  Millions$ 47.462  Millions
Ocular Therapeutix Inc   0.07 $ 50.384  Millions$ 704.388  Millions
Stoke Therapeutics Inc   0.07 $ 28.211  Millions$ 415.592  Millions
Intellia Therapeutics Inc   0.06 $ 52.887  Millions$ 840.157  Millions
Stablecoin Development Corporation  0.06 $ 7.246  Millions$ 126.127  Millions
Seer Inc   0.05 $ 14.248  Millions$ 266.663  Millions
Recursion Pharmaceuticals Inc   0.05 $ 68.232  Millions$ 1,312.008  Millions
Abcellera Biologics Inc   0.05 $ 67.858  Millions$ 1,367.875  Millions
Lenz Therapeutics Inc   0.05 $ 12.359  Millions$ 256.189  Millions
Co diagnostics Inc   0.05 $ 0.859  Millions$ 18.906  Millions
Cytomx Therapeutics Inc   0.04 $ 14.027  Millions$ 314.207  Millions
Metagenomi Therapeutics Inc   0.04 $ 7.086  Millions$ 187.286  Millions
Aclaris Therapeutics Inc   0.03 $ 6.401  Millions$ 188.758  Millions
Ideaya Biosciences Inc   0.03 $ 36.535  Millions$ 1,166.348  Millions
Dbv Technologies S a   0.02 $ 3.844  Millions$ 234.675  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.